1. A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial.
- Author
-
Rondanelli M, Gasparri C, Cavioni A, Sivieri C, Barrile GC, Mansueto F, and Perna S
- Subjects
- Humans, Male, Aged, Female, Aged, 80 and over, Valerates administration & dosage, Valerates pharmacology, Tumor Necrosis Factor-alpha blood, Tumor Necrosis Factor-alpha metabolism, Butyrates, Double-Blind Method, Haptoglobins, C-Reactive Protein metabolism, C-Reactive Protein analysis, Protein Precursors, Dietary Supplements, Sarcopenia drug therapy, Sarcopenia prevention & control, Carnosine administration & dosage, Lactoferrin administration & dosage, Lactoferrin pharmacology, Magnesium administration & dosage, Muscle, Skeletal drug effects, Muscle, Skeletal metabolism, Permeability drug effects
- Abstract
Adequate diet, physical activity, and dietary supplementation with muscle-targeted food for special medical purposes (FSMP) or dietary supplement (DS) are currently considered fundamental pillars in sarcopenia treatment. The aim of this study is to evaluate the effectiveness of a DS (containing hydroxy-methyl-butyrate, carnosine, and magnesium, for its action on muscle function and protein synthesis and butyrate and lactoferrin for their contribution to the regulation of gut permeability and antioxidant/anti-inflammation activity) on muscle mass (assessed by dual X-ray absorptiometry (DXA)), muscle function (by handgrip test, chair test, short physical performance battery (SPPB) test, and walking speed test), inflammation (tumor necrosis factor-alpha (TNF-a), C-reactive protein (CRP), and visceral adipose tissue (VAT)) and gut axis (by zonulin). A total of 59 participants (age 79.7 ± 4.8 years, body mass index 20.99 ± 2.12 kg/m
2 ) were enrolled and randomly assigned to intervention ( n = 30) or placebo ( n = 28). The skeletal muscle index (SMI) significantly improved in the supplemented group compared to the placebo one, +1.02 (CI 95%: -0.77; 1.26), p = 0.001; a significant reduction in VAT was observed in the intervention group, -70.91 g (-13.13; -4.70), p = 0.036. Regarding muscle function, all the tests significantly improved ( p = 0.001) in the supplemented group compared to the placebo one. CRP, zonulin, and TNF-alpha significantly decreased ( p = 0.001) in intervention, compared to placebo, -0.74 mg/dL (CI 95%: -1.30; -0.18), -0.30 ng/mL (CI 95%: -0.37; -0.23), -6.45 pg/mL (CI 95%: -8.71; -4.18), respectively. This DS improves muscle mass and function, and the gut muscle has emerged as a new intervention target for sarcopenia.- Published
- 2024
- Full Text
- View/download PDF